Page 4 - Kronos Bio News Today

KB-0742 is under clinical development by Kronos Bio and currently in Phase II for Ewing Sarcoma.

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors Showed...

Demonstrated on-mechanism, single agent anti-tumor activity in heavily pre-treated patients with transcriptionally addicted solid tumors

Interim Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 KB-0742 Study at AACR-NCI-EORTC October 13, 2023 ...

Management to host conference call and webcast on October 13 at 4:30 PM ET with key opinion leader and KB-0742 trial investigator, Miguel Villalona-Calero, M.D., of City of HopeSAN MATEO, Calif., and...

MIT spinout Kronos Bio, founded by Associate Professor Angela Koehler, studies the complex signaling networks of cancer cells to find new drug targets. Proteins called transcription factors are like...

The MIT spinout Kronos Bio, founded by Associate Professor Angela Koehler, studies the complex signaling networks of cancer cells to find new ways to stop their growth.

Kronos Bio (NASDAQ:KRON – Get Free Report) had its price target reduced by analysts at HC Wainwright from $10.00 to $9.00 in a report released on Monday, Marketbeat.com reports. The firm presently has a “buy” rating on the stock. Kronos Bio Price Performance Shares of KRON stock opened at $1.42 on Monday. The business has […]

Kronos Bio (NASDAQ:KRON – Free Report) had its target price trimmed by HC Wainwright from $10.00 to $9.00 in a research note released on Monday, MarketBeat reports. The brokerage currently has a buy rating on the stock. Kronos Bio Trading Down 1.4 % Shares of Kronos Bio stock opened at $1.42 on Monday. The company […]

Key Insights Given the large stake in the stock by institutions, Kronos Bio's stock price might be vulnerable to their...